{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:49:26Z","timestamp":1794606566275,"version":"4.9.1"},"reference-count":108,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:00:00Z","timestamp":1698364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The peritoneum is a common site of metastases for gastrointestinal tumors that predicts a poor outcome. In addition to decreased survival, peritoneal metastases (PMs) can significantly impact quality of life from the resulting ascites and bowel obstructions. The peritoneum has been a target for regional therapies due to the unique properties of the blood\u2013peritoneum barrier. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) have become accepted treatments for limited-volume peritoneal disease in appendiceal, ovarian, and colorectal malignancies, but there are limitations. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) improves drug distribution and tissue penetration, allowing for a minimally invasive application for patients who are not CRS\/HIPEC candidates based on high disease burden. PIPAC is an emerging treatment that may convert the patient to resectable disease, and may increase survival without major morbidity, as indicated by many small studies. In this review, we discuss the rationale and benefits of PIPAC, as well as sentinel papers describing its application for gastric, colorectal, appendiceal, and pancreatobiliary PMs. While no PIPAC device has yet met FDA approval, we discuss next steps needed to incorporate PIPAC into neoadjuvant\/adjuvant treatment paradigms, as well as palliative settings. Data on active clinical trials using PIPAC are provided.<\/jats:p>","DOI":"10.3390\/jcm12216799","type":"journal-article","created":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T11:50:18Z","timestamp":1698407418000},"page":"6799","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["PIPAC for Gastrointestinal Malignancies"],"prefix":"10.3390","volume":"12","author":[{"given":"Sara K.","family":"Daniel","sequence":"first","affiliation":[{"name":"Department of Surgery, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice J.","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Surgery, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byrne","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Stanford University, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/01.sla.0000197382.43208.a5","article-title":"Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma","volume":"243","author":"Sarela","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1245\/s10434-018-6335-7","article-title":"Palliative Management of Peritoneal Metastases","volume":"25","author":"Lambert","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e15914","DOI":"10.15252\/emmm.202215914","article-title":"The molecular biology of peritoneal metastatic disease","volume":"15","author":"Bootsma","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/path.4281","article-title":"Carcinoma-associated fibroblasts derive from mesothelial cells via mesothelial-to-mesenchymal transition in peritoneal metastasis","volume":"231","author":"Sandoval","year":"2013","journal-title":"J. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Li, J., and Guo, T. (2022). Role of Peritoneal Mesothelial Cells in the Progression of Peritoneal Metastases. Cancers, 14.","DOI":"10.3390\/cancers14122856"},{"key":"ref_7","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.V72225","article-title":"Small-solute transport across specific peritoneal tissue surfaces in the rat","volume":"7","author":"Flessner","year":"1996","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_9","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Harper, M.M., Kim, J., and Pandalai, P.K. (2022). Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies. J. Clin. Med., 11.","DOI":"10.3390\/jcm11102840"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/jso.21051","article-title":"Drugs carrier solutions temperature in hyperthermic intraperitoneal chemotherapy","volume":"98","author":"Kusamura","year":"2008","journal-title":"J. Surg. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/pp-2017-0012","article-title":"Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview","volume":"2","author":"Sugarbaker","year":"2017","journal-title":"Pleura Perit."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.21037\/jgo-2020-03","article-title":"Intraperitoneal paclitaxel: Pharmacology, clinical results and future prospects","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00464-011-1964-y","article-title":"Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: Proof of concept","volume":"26","author":"Solass","year":"2012","journal-title":"Surg. Endosc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","article-title":"Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model","volume":"142","author":"Khosrawipour","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.sla.0000218089.61635.5f","article-title":"High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis","volume":"244","author":"Esquis","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/00001813-199607000-00016","article-title":"Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration","volume":"7","author":"Jacquet","year":"1996","journal-title":"Anticancer Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/SLA.0b013e3182582b38","article-title":"High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: An experimental study","volume":"256","author":"Facy","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20190013","DOI":"10.1515\/pp-2019-0013","article-title":"Anaesthesia considerations and techniques for Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC)","volume":"5","author":"Shree","year":"2020","journal-title":"Pleura Perit."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","article-title":"Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: An innovative approach to treat peritoneal carcinomatosis","volume":"14","author":"Robella","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11605-018-3916-5","article-title":"How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures","volume":"22","author":"Tempfer","year":"2018","journal-title":"J. Gastrointest. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/pp-2016-0021","article-title":"Single-port access for Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): Technique, feasibility and safety","volume":"1","author":"Vaira","year":"2016","journal-title":"Pleura Perit."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ejso.2022.05.001","article-title":"Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study","volume":"48","author":"Robella","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1245\/s10434-020-09508-0","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy for Colorectal Peritoneal Metastases","volume":"28","author":"Tabchouri","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00432-022-04517-w","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): A prospective single-center registry study","volume":"149","author":"Eberth","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/B978-0-12-817870-6.00010-9","article-title":"Chapter 10\u2014Optimizing intraperitoneal drug delivery: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"Volume 3","author":"Reymond","year":"2020","journal-title":"Drug Delivery Trends"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/02656736.2019.1704891","article-title":"PIPAC versus HIPEC: Cisplatin spatial distribution and diffusion in a swine model","volume":"37","author":"Davigo","year":"2020","journal-title":"Int. J. Hyperth."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1245\/s10434-015-4954-9","article-title":"Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)","volume":"23","author":"Khosrawipour","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mimouni, M., Richard, C., Adenot, P., Letheule, M., Tarrade, A., Sandra, O., Dahirel, M., Lilin, T., Lecuelle, B., and G\u00e9lin, V. (2021). Pressurized intra-peritoneal aerosol chemotherapy (PIPAC): Increased intraperitoneal pressure does not affect distribution patterns but leads to deeper penetration depth of doxorubicin in a sheep model. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07955-w"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1245\/s10434-020-09332-6","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy Enhanced by Electrostatic Precipitation (ePIPAC) for Patients with Peritoneal Metastases","volume":"28","author":"Taibi","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Robella, M., De Simone, M., Berchialla, P., Argenziano, M., Borsano, A., Ansari, S., Abollino, O., Ficiar\u00e0, E., Cinquegrana, A., and Cavalli, R. (2021). A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis. Cancers, 13.","DOI":"10.3390\/cancers13051060"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-20-2152","article-title":"PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases","volume":"27","author":"Kim","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_34","first-page":"20180128","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure","volume":"3","author":"Graversen","year":"2018","journal-title":"Pleura Perit."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00384-022-04182-y","article-title":"Assessment of postoperative pain after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of peritoneal metastasis","volume":"37","author":"Tidadini","year":"2022","journal-title":"Int. J. Color. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10585-018-9895-9","article-title":"Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): Report of two cases and literature survey","volume":"35","author":"Graversen","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","article-title":"Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial","volume":"158","year":"2023","journal-title":"JAMA Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12957-019-1633-5","article-title":"Comparing the cytotoxicity of taurolidine, mitomycin C, and oxaliplatin on the proliferation of in vitro colon carcinoma cells following pressurized intra-peritoneal aerosol chemotherapy (PIPAC)","volume":"17","author":"Schubert","year":"2019","journal-title":"World J. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","article-title":"Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis","volume":"43","author":"Alyami","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1515\/pp-2022-0116","article-title":"Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: Rationale and design","volume":"7","author":"Raoof","year":"2022","journal-title":"Pleura Perit."},{"key":"ref_42","first-page":"1","article-title":"Feasibility and Safety of Taxane-PIPAC in Patients with Peritoneal Malignancies\u2014A Retrospective Bi-institutional Study","volume":"14","author":"Mehta","year":"2022","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_43","first-page":"20180112","article-title":"Intraperitoneal aerosolization of albumin-stabilized paclitaxel nanoparticles (Abraxane\u2122) for peritoneal carcinomatosis\u2014A phase I first-in-human study","volume":"3","author":"Graversen","year":"2018","journal-title":"Pleura Perit."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e067691","DOI":"10.1136\/bmjopen-2022-067691","article-title":"Nab-PIPAC: A phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity","volume":"13","author":"Lang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s00464-019-07076-3","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) might increase the risk of anastomotic leakage compared to HIPEC: An experimental study","volume":"34","author":"Tavernier","year":"2020","journal-title":"Surg. Endosc."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejso.2018.05.020","article-title":"Occupational exposure to cisplatin\/oxaliplatin during Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)?","volume":"44","author":"Ametsbichler","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1245\/s10434-019-07695-z","article-title":"Comparison of Tissue and Blood Concentrations of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy","volume":"26","author":"Bucur","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1245\/s10434-020-08843-6","article-title":"Implications of Postoperative Complications for Survival after Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative","volume":"27","author":"Gamboa","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0310057X211064904","article-title":"Preoperative cardiopulmonary exercise testing improves risk assessment of morbidity and length of stay following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy","volume":"50","author":"Pillinger","year":"2022","journal-title":"Anaesth. Intensive Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.suronc.2020.05.006","article-title":"Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis","volume":"34","author":"Schena","year":"2020","journal-title":"Surg. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejso.2019.03.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in association with systemic chemotherapy and bevacizumab, evaluation of safety and feasibility. A single center comparative study","volume":"47","author":"Siebert","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1245\/s10434-023-13278-w","article-title":"Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence\u2014The PIPAC-OPC4 Study","volume":"30","author":"Graversen","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12957-016-1008-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"14","author":"Girshally","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12029-022-00843-x","article-title":"Oncological Outcomes After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Peritoneal Carcinomatosis","volume":"54","author":"Tidadini","year":"2023","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","article-title":"Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1245\/s10434-017-5838-y","article-title":"Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy","volume":"24","author":"Ikoma","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1245\/s10434-021-10724-5","article-title":"Symptomatic Recurrence and Survival Outcomes After Curative Treatment of Gastric Cancer: Does Intensive Follow-up Evaluation Improve Survival?","volume":"29","author":"Diniz","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1245\/s10434-022-12761-0","article-title":"Cytoreduction and HIPEC for Gastric Carcinomatosis: Multi-institutional Analysis of Two Phase II Clinical Trials","volume":"30","author":"Green","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ejso.2020.11.139","article-title":"Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients","volume":"47","author":"Ji","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.suronc.2019.01.005","article-title":"HIPEC and CRS in peritoneal metastatic gastric cancer\u2014Who really benefits?","volume":"28","author":"Hotopp","year":"2019","journal-title":"Surg. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/pp-2016-0017","article-title":"Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: An open-label, Phase-2 study (PIPAC-GA2)","volume":"1","author":"Khomyakov","year":"2016","journal-title":"Pleura Perit."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Low-Dose Cisplatin and Doxorubicin in Gastric Peritoneal Metastasis","volume":"20","author":"Nadiradze","year":"2016","journal-title":"J. Gastrointest. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5230\/jgc.2018.18.e37","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study","volume":"18","author":"Gockel","year":"2018","journal-title":"J. Gastric Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1758835919846402","DOI":"10.1177\/1758835919846402","article-title":"Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: A phase II study","volume":"11","author":"Struller","year":"2019","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10585-020-10023-5","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: A descriptive cohort study","volume":"37","author":"Graversen","year":"2020","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1245\/s10434-021-10860-y","article-title":"Clinical Outcome for Patients Managed with Low-Dose Cisplatin and Doxorubicin Delivered as Pressurized Intraperitoneal Aerosol Chemotherapy for Unresectable Peritoneal Metastases of Gastric Cancer","volume":"29","author":"Sindayigaya","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s12029-021-00698-8","article-title":"Effect of Pressurized Intraperitoneal Aerosol Chemotherapy on the Survival Rate of Patients with Peritoneal Carcinomatosis of Gastric Origin","volume":"53","author":"Tidadini","year":"2022","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Benson","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br. J. Surg."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): A randomised, phase 3 study","volume":"21","author":"Glehen","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Arjona-S\u00e1nchez, A., Barrios, P., Boldo-Roda, E., Camps, B., Carrasco-Campos, J., Concepci\u00f3n Mart\u00edn, V., Garc\u00eda-Fadrique, A., Guti\u00e9rrez-Calvo, A., Morales, R., and Ortega-P\u00e9rez, G. (2018). HIPECT4: Multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra-peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4096-0"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1634\/theoncologist.2017-0081","article-title":"Appendiceal Mucinous Neoplasms: Diagnosis and Management","volume":"22","author":"Shaib","year":"2017","journal-title":"Oncologist"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s10434-006-9708-2","article-title":"Appendiceal neoplasms with peritoneal dissemination: Outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy","volume":"13","author":"Stewart","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1634\/theoncologist.2014-0294","article-title":"Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients with Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis from Three Tertiary Care Centers","volume":"20","author":"Shaib","year":"2015","journal-title":"Oncologist"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s10147-017-1217-8","article-title":"Repeat cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal carcinomatosis of appendiceal origin","volume":"23","author":"Kitai","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s00268-022-06498-w","article-title":"An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"46","author":"Mercier","year":"2022","journal-title":"World J. Surg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1245\/s10434-019-08064-6","article-title":"Health-Related Quality of Life After Cytoreductive Surgery\/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin","volume":"27","author":"Moaven","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/codi.13130","article-title":"Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis","volume":"18","author":"Solass","year":"2016","journal-title":"Color. Dis."},{"key":"ref_84","first-page":"20200109","article-title":"Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)-directed treatment of peritoneal metastasis in end-stage colo-rectal cancer patients","volume":"5","author":"Graversen","year":"2020","journal-title":"Pleura Perit."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1245\/s10434-020-09558-4","article-title":"Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC)","volume":"28","author":"Rovers","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Somashekhar, S.P., Abba, J., Sgarbura, O., Alyami, M., Teixeira Farinha, H., Rao, R.G., Willaert, W., H\u00fcbner, M., and PIPAC Study Group (2022). Assessment of Treatment Response after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Appendiceal Peritoneal Metastases. Cancers, 14.","DOI":"10.3390\/cancers14204998"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"7814","DOI":"10.1245\/s10434-023-13941-2","article-title":"Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA","volume":"30","author":"Raoof","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"694","DOI":"10.6004\/jnccn.2023.0035","article-title":"NCCN Guidelines\u00ae Insights: Biliary Tract Cancers, Version 2.2023","volume":"21","author":"Benson","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPA.0b013e31825abf8c","article-title":"Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: A population-based study","volume":"42","author":"Thomassen","year":"2013","journal-title":"Pancreas"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40792-016-0135-8","article-title":"Long-term survival of a recurrent gallbladder carcinoma patient with lymph node and peritoneal metastases after multidisciplinary treatments: A case report","volume":"2","author":"Tomita","year":"2016","journal-title":"Surg. Case Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.ejso.2018.04.023","article-title":"Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups","volume":"44","author":"Amblard","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.21037\/jgo-20-46","article-title":"Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection","volume":"12","author":"Tentes","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.21037\/jgo-2020-02","article-title":"Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: Final clinical and pharmacologic data from a phase II protocol and recommended future directions","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1245\/s10434-022-12328-z","article-title":"Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study","volume":"30","author":"Grotz","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.21037\/jgo-20-238","article-title":"Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: A pilot study of the clinical trial EudraCT 2016-004298-41","volume":"12","author":"Sanchez","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1245\/s10434-021-10254-0","article-title":"A Prospective, Phase I\/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy after Oncological Resection of Pancreatic Adenocarcinoma","volume":"28","author":"Yurttas","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10585-017-9849-7","article-title":"Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"34","author":"Graversen","year":"2017","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_98","first-page":"373","article-title":"First Clinical Data of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as Salvage Therapy for Peritoneal Metastatic Biliary Tract Cancer","volume":"38","author":"Falkenstein","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1758835920940887","DOI":"10.1177\/1758835920940887","article-title":"Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma","volume":"12","author":"Sgarbura","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/jclinpath-2020-206607","article-title":"Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC","volume":"74","author":"Nielsen","year":"2021","journal-title":"J. Clin. Pathol."},{"key":"ref_101","first-page":"4596176","article-title":"Impact of Pressurized Intraperitoneal Aerosol Chemotherapy on Quality of Life and Symptoms in Patients with Peritoneal Carcinomatosis: A Retrospective Cohort Study","volume":"2017","author":"Grass","year":"2017","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2020.09.010","article-title":"A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers","volume":"140","author":"Dumont","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1007\/s00464-021-08802-6","article-title":"Patient-reported outcomes during repetitive oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for isolated unresectable colorectal peritoneal metastases in a multicenter, single-arm, phase 2 trial (CRC-PIPAC)","volume":"36","author":"Lurvink","year":"2022","journal-title":"Surg. Endosc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ejso.2015.06.001","article-title":"Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)","volume":"41","author":"Odendahl","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1515\/pp-2021-0142","article-title":"Body composition and immunonutritional status in patients treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC) for gastrointestinal peritoneal metastases: A prospective single-center analysis","volume":"7","author":"Rotolo","year":"2022","journal-title":"Pleura Perit."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejso.2022.07.024","article-title":"Hospitalization cost of Pressurized Intraperitoneal Aerosol chemotherapy (PIPAC)","volume":"49","author":"Tidadini","year":"2023","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejso.2021.08.024","article-title":"Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis","volume":"48","author":"Javanbakht","year":"2022","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.ejso.2019.06.018","article-title":"Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis","volume":"45","author":"Willaert","year":"2019","journal-title":"Eur. J. Surg. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6799\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:12:51Z","timestamp":1760130771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,27]]},"references-count":108,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jcm12216799"],"URL":"https:\/\/doi.org\/10.3390\/jcm12216799","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,27]]}}}